Clinical Trials · NCT02020616
A Study of the Safety and Effectiveness of LY3053102 in Participants With Type 2 Diabetes
- Phase
- Phase 1/Phase 2
- Recruitment status
- Terminated
- Sponsor
- Eli Lilly and Company
- Enrollment
- 60
- Start date
- Dec 2013
- Locations
- 5 sites, United States
- Primary endpoint
- Change From Baseline in Hemoglobin A1c (HbA1c) at 12-Week Endpoint